G1 THERAPEUTICS (NASDAQ:GTHX) – Stock analysts at Wedbush issued their Q1 2018 earnings per share (EPS) estimates for shares of G1 THERAPEUTICS in a research report issued to clients and investors on Thursday. Wedbush analyst D. Nierengarten forecasts that the company will post earnings of ($0.52) per share for the quarter. Wedbush has a “Outperform” rating and a $31.00 price target on the stock. Wedbush also issued estimates for G1 THERAPEUTICS’s Q2 2018 earnings at ($0.55) EPS, Q3 2018 earnings at ($0.59) EPS and Q4 2018 earnings at ($0.61) EPS.

A number of other equities analysts also recently issued reports on the stock. J P Morgan Chase & Co began coverage on shares of G1 THERAPEUTICS in a research note on Monday, June 12th. They set an “overweight” rating and a $23.00 price objective on the stock. Needham & Company LLC began coverage on shares of G1 THERAPEUTICS in a research note on Monday, June 12th. They set a “buy” rating and a $34.00 price objective on the stock. Finally, Cowen and Company reiterated a “buy” rating on shares of G1 THERAPEUTICS in a research note on Wednesday.

TRADEMARK VIOLATION WARNING: This article was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.watchlistnews.com/g1-therapeutics-gthx-to-post-q1-2018-earnings-of-0-52-per-share-wedbush-forecasts/1472985.html.

G1 THERAPEUTICS (NASDAQ:GTHX) traded up 0.08% during midday trading on Friday, reaching $12.60. The company’s stock had a trading volume of 16,067 shares. The firm has a 50 day moving average price of $15.42 and a 200 day moving average price of $16.24. The firm’s market cap is $18.65 million. G1 THERAPEUTICS has a one year low of $12.04 and a one year high of $20.60.

G1 THERAPEUTICS (NASDAQ:GTHX) last posted its quarterly earnings data on Wednesday, August 9th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by $0.48.

A number of large investors have recently made changes to their positions in GTHX. Alps Advisors Inc. purchased a new stake in shares of G1 THERAPEUTICS during the second quarter valued at $444,000. Chartwell Investment Partners LLC purchased a new stake in shares of G1 THERAPEUTICS during the second quarter valued at $1,538,000. Victory Capital Management Inc. purchased a new stake in shares of G1 THERAPEUTICS during the second quarter valued at $889,000. Franklin Resources Inc. purchased a new stake in shares of G1 THERAPEUTICS during the second quarter valued at $10,651,000. Finally, Laurion Capital Management LP purchased a new stake in shares of G1 THERAPEUTICS during the second quarter valued at $3,488,000. Institutional investors own 4.57% of the company’s stock.

In other G1 THERAPEUTICS news, major shareholder Clay Thorp acquired 133,333 shares of the company’s stock in a transaction dated Monday, May 22nd. The shares were purchased at an average cost of $15.00 per share, for a total transaction of $1,999,995.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Ra Capital Healthcare Fund Lp acquired 400,000 shares of the company’s stock in a transaction dated Monday, May 22nd. The shares were acquired at an average price of $15.00 per share, for a total transaction of $6,000,000.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 833,333 shares of company stock worth $12,499,995.

About G1 THERAPEUTICS

G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.

Receive News & Ratings for G1 THERAPEUTICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 THERAPEUTICS and related companies with Analyst Ratings Network's FREE daily email newsletter.